Kain50 mg/ml

Approved Indication

Kain is indicated as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation, and as an induction agent prior to administration of other general anesthetics. It is also used to supplement low-potency agents such as nitrous oxide.

Guideline-Supported / Common Clinical Uses

• Procedural sedation and analgesia (e.g. fracture reduction, wound care, burn dressing changes) in emergency and outpatient settings, at sub-anesthetic doses.
• Acute pain management as a low-dose adjunct to opioid analgesia, particularly in trauma and emergency medicine.

Off-Label Uses

Kain is used off-label, at very low sub-anesthetic ("sub-dissociative") doses and only under specialist supervision, for:

• Adjunct treatment of certain refractory chronic pain conditions (e.g. complex regional pain syndrome), usually as part of a multimodal pain program.
• Treatment-resistant depression, administered by intravenous infusion in specialized psychiatric or anesthesia settings with continuous monitoring. (A related, chemically distinct enantiomer product is separately FDA-approved as an intranasal antidepressant; that is a different medicine from Kain itself.)

Kain is a controlled substance with recognized potential for misuse and must never be self-administered outside a supervised medical setting.

Each mL of injectable solution contains Ketamine hydrochloride equivalent to Ketamine base, commonly available in strengths of 50 mg/mL (also formulated as 10 mg/mL and 100 mg/mL in some markets), supplied as a clear, colourless, multi-dose injectable solution for intravenous or intramuscular use.

Kain is a rapid-acting, non-barbiturate general anesthetic that produces a unique state known as "dissociative anesthesia," characterised by profound analgesia, normal or slightly enhanced skeletal muscle tone, cardiovascular and respiratory stimulation, and occasionally a transient and minimal respiratory depression.

It is chemically classified as an arylcyclohexylamine and acts primarily through non-competitive antagonism of the NMDA (N-methyl-D-aspartate) glutamate receptor. Kain is administered by intravenous or intramuscular injection only in monitored clinical settings by personnel trained in airway management and general anesthesia.

General (dissociative) anesthetic agent; NMDA-receptor antagonist.

Mechanism

Ketamine is a non-competitive antagonist at the NMDA receptor-ion channel complex, which blocks glutamate-mediated excitatory neurotransmission and produces dissociation between the cortical and limbic systems, resulting in a cataleptic, amnesic, and analgesic state distinct from other general anesthetics. It also interacts, to a lesser degree, with opioid, monoaminergic, muscarinic and other receptor systems, contributing to its analgesic and sympathomimetic effects.

Pharmacokinetics

• Onset: Approximately 30 seconds after intravenous administration and 3-4 minutes after intramuscular administration.
• Duration: Typically 5-10 minutes of surgical anesthesia after a standard IV induction dose, and 12-25 minutes after a standard IM dose; full orientation may take longer to return.
• Metabolism: Extensively hepatic, chiefly via N-demethylation (CYP3A4 and related isoenzymes) to norketamine, an active metabolite with reduced potency.
• Elimination: Primarily renal, as metabolites; elimination half-life is approximately 2-3 hours.

Ketamine characteristically increases heart rate, blood pressure and cardiac output (sympathomimetic stimulation), which distinguishes it from most other anesthetic agents that are cardiodepressant.

Kain is given by slow intravenous injection (over approximately 60 seconds) or by intramuscular injection, and by continuous IV infusion for maintenance of anesthesia/sedation. It must be administered only in a setting equipped for continuous monitoring of heart rate, blood pressure, oxygen saturation, and airway/respiratory status, by personnel trained in resuscitation and airway management. Kain is not intended for unsupervised self-administration under any circumstance.

Clinically Significant Interactions

• Barbiturates and opioids/narcotics: Concurrent use with Kain may prolong recovery time; barbiturate and Kain solutions are chemically incompatible in the same syringe and must not be mixed.
• Other CNS depressants (benzodiazepines, sedatives, alcohol): Additive sedation and respiratory depression; often used deliberately in combination (e.g. with a benzodiazepine) to reduce emergence reactions, but requires closer respiratory monitoring.
• Thyroid hormone preparations: Concomitant use has been associated with marked elevations in blood pressure and heart rate.
• Sympathomimetics and vasopressors: May potentiate the hypertensive and tachycardic effects of Kain.

Co-administration of a benzodiazepine and use of a quiet recovery environment can reduce the frequency and severity of emergence reactions associated with Kain.

Pregnancy: Safe use of Kain in human pregnancy, including obstetric use, has not been established, and such use is generally not recommended. Kain should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; always consult a physician before use in pregnancy.

Lactation: Data on excretion of Kain into human breast milk are limited. Because of potential effects on the infant, a decision should be made whether to discontinue breastfeeding or avoid Kain, taking into account the importance of the drug to the mother, in consultation with a physician.

• Kain must be administered only in settings with continuous cardiorespiratory monitoring available, by personnel trained in airway management and resuscitation.
• Use with caution in patients with cardiovascular disease (hypertension, ischemic heart disease, heart failure) because Kain characteristically raises heart rate and blood pressure.
• Use with caution in patients with elevated intracranial pressure, intracranial mass lesions, or elevated intraocular pressure, or open eye injuries.
• Use with caution in patients with a history of psychosis or other significant psychiatric illness, as Kain may precipitate or worsen psychotic symptoms.
• Emergence reactions (see Side Effects) are more frequent in adults; pre-treatment or co-administration with a benzodiazepine and a calm recovery environment can reduce their incidence.
• Kain is a controlled substance with recognized potential for abuse, misuse, diversion, and dependence; it must never be self-administered and should be stored and dispensed under appropriate controlled-substance safeguards.
• Avoid hazardous activities (e.g. driving, operating machinery) until full recovery of cognitive and motor function after receiving Kain.

Overdosage or excessively rapid administration of Kain can cause profound respiratory depression or apnea, severe cardiovascular instability, and prolonged unresponsiveness. If overdose of Kain is suspected, seek immediate medical attention or contact emergency services/poison control without delay. Management is supportive, with priority given to securing the airway and providing ventilatory support; mechanical ventilatory assistance is generally preferred over the use of analeptic (respiratory-stimulant) drugs. Complete recovery is typical with prompt supportive care, even after unintentionally large doses.

Store at controlled room temperature, 20-25°C (68-77°F); protect from light. Keep out of reach of children, and store under locked, controlled-substance conditions in accordance with local regulations, as Kain has recognized potential for misuse.

Pediatric Use

Original labeling states that safety and efficacy of Kain in patients below 16 years of age have not been formally established. Nonetheless, weight-based dosing of Kain is widely used off-label for pediatric anesthesia and procedural sedation under the supervision of specialists experienced in pediatric airway management, following current specialty guidance.

Elderly

Use with caution in elderly patients, particularly those with cardiovascular disease, as they may be more sensitive to the hemodynamic (blood pressure/heart rate) effects of Kain; consider lower doses with close monitoring.

Hepatic/Renal Impairment

No formal dose-adjustment guidelines exist. Because Kain is cleared hepatically, use with caution and titrate carefully in patients with significant hepatic impairment.

Pregnancy and Breastfeeding

See Pregnancy and Lactation above.

Kain is typically used for the duration of a single anesthetic, sedation, or analgesic episode (minutes to a few hours), determined by the procedure and the clinician's judgment, with additional maintenance doses given as needed. It is not intended for ongoing self-administration. Off-label use for depression or chronic pain follows structured, time-limited infusion protocols under specialist supervision, with duration determined by the treating specialist based on response and safety monitoring.

Dissociative (general) anesthetic; NMDA-receptor antagonist; controlled substance (recognized potential for misuse/dependence).

Non-competitive antagonism of the NMDA (N-methyl-D-aspartate) glutamate receptor-ion channel complex in the central nervous system, producing dissociation between the thalamocortical and limbic systems that manifests as profound analgesia, amnesia, and catalepsy ("dissociative anesthesia"), with additional minor interactions at opioid, monoaminergic and muscarinic receptor sites.

Formal labeling states that safety and effectiveness of Kain in children under 16 years of age have not been established. In current clinical practice, however, Kain is widely and routinely used off-label, at weight-based doses, for pediatric procedural sedation and general anesthesia, based on extensive published experience and specialty-society guidance, provided it is given by clinicians experienced in pediatric airway management with full monitoring available. Parents/guardians should discuss the specific risks and benefits for their child with the treating specialist.